Table 2.
Characteristics of tumor markers for targeted imaging
| Target | % with positive LNM expression | % with positive EAC expression | T/N ratio LNM | T/N ratio EAC | Agreement EAC and LNM expression | Previously targeted imaging |
|---|---|---|---|---|---|---|
| CA-IX | 4 | 34 | > 10 | > 10 | 65 | Clinical study [13] |
| CEA | 68 | 54 | > 10 | 3.62 | 72 | Clinical study [27] |
| c-MET | 4 | 10 | > 10 | > 10 | 87 | Clinical study [32] |
| EGFR | 4 | 3 | > 10 | > 10 | 96 | Clinical study [33] |
| EMA | 100 | 98 | > 10 | 1.00 | 100 | Clinical study [34] |
| EpCAM | 100 | 98 | > 10 | > 10 | 100 | Preclinical [29] |
| HER-2 | 13 | 11 | > 10 | > 10 | 84 | Clinical study [35] |
| uPAR | 8 | 15 | 1.09 | > 10 | 89 | Clinical study [36] |
| VEGF-A | 85 | 92 | 1.21 | 0.91 | 80 | Clinical study [12] |
| VEGFR2 | 2 | 7 | 0.42 | 0.33 | 93 | Preclinical [37] |
CA-IX carbonic anhydrase IX, CEA carcinoembryonic antigen, c-MET hepatic growth factor receptor, EAC esophageal adenocarcinoma, EGFR epidermal growth factor receptor , EMA epithelial membrane antigen, EpCAM epithelial cell adhesion molecule, HER-2 human epidermal growth factor receptor 2, LNM lymph node metastases, T/N ratio EAC tumor to background esophageal adenocarcinoma and nonmalignant esophageal tissue, T/N ratio LNM tumor to background ratio lymph node metastases and nonmalignant lymph nodes, uPAR urokinase plasminogen activator receptor, VEGF-A vascular endothelial growth factor-A, VEGFR2 VEGF receptor 2